LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel ; Online: UGT1A1

    Peeters, Sofía Lj / Deenen, Maarten J / Thijs, Anna Mj / Hulshof, Emma C / Mathijssen, Ron Hj / Gelderblom, Hans / Guchelaar, Henk-Jan / Swen, Jesse J

    Pharmacogenomics

    2023  Band 24, Heft 8, Seite(n) 435–439

    Abstract: Tweetable abstract ... ...

    Abstract Tweetable abstract Pretreatment
    Mesh-Begriff(e) Humans ; Irinotecan/adverse effects ; Camptothecin/adverse effects ; Patient Safety ; Genotype ; Neoplasms/drug therapy ; Glucuronosyltransferase/genetics
    Chemische Substanzen Irinotecan (7673326042) ; Camptothecin (XT3Z54Z28A) ; Glucuronosyltransferase (EC 2.4.1.17)
    Sprache Englisch
    Erscheinungsdatum 2023-07-20
    Erscheinungsland England
    Dokumenttyp Editorial
    ZDB-ID 2019513-8
    ISSN 1744-8042 ; 1462-2416
    ISSN (online) 1744-8042
    ISSN 1462-2416
    DOI 10.2217/pgs-2023-0096
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5247: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel: Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol.

    van der Ploeg, Phyllis / Hendrikse, Cynthia Se / Thijs, Anna Mj / Westgeest, Hans M / Smedts, Huberdina Pm / Vos, M Caroline / Jalving, Mathilde / Lok, Christianne Ar / Boere, Ingrid A / van Ham, Maaike Apc / Ottevanger, Petronella B / Westermann, Anneke M / Mom, Constantijne H / Lalisang, Roy I / Lambrechts, Sandrina / Bekkers, Ruud Lm / Piek, Jurgen Mj

    Heliyon

    2023  Band 10, Heft 1, Seite(n) e23170

    Abstract: Objective: Ovarian cancer is the fifth cause of cancer-related death among women. The benefit of targeted therapy for ovarian cancer patients is limited even if treatment is stratified by molecular signature. There remains a high unmet need for ... ...

    Abstract Objective: Ovarian cancer is the fifth cause of cancer-related death among women. The benefit of targeted therapy for ovarian cancer patients is limited even if treatment is stratified by molecular signature. There remains a high unmet need for alternative diagnostics that better predict targeted therapy, as current diagnostics are generally inaccurate predictors. Quantitative assessment of functional signal transduction pathway (STP) activity from mRNA measurements of target genes is an alternative approach. Therefore, we aim to identify aberrantly activated STPs in tumour tissue of patients with recurrent ovarian cancer and start
    Study design: Patients with recurrent ovarian cancer and either 1) have platinum-resistant disease, 2) refrain from standard therapy or 3) are asymptomatic and not yet eligible for standard therapy will be included in this multi-centre prospective cohort study with multiple stepwise executed treatment arms. Targeted therapy will be available for patients with aberrantly high functional activity of the oestrogen receptor, androgen receptor, phosphoinositide 3-kinase or Hedgehog STP. The primary endpoint of this study is the progression-free survival (PFS) ratio (PFS2/PFS1 ratio) according to RECIST 1.1 determined by the PFS on matched targeted therapy (PFS2) compared to PFS on prior therapy (PFS1). Secondary endpoints include among others best overall response, overall survival, side effects, health-related quality of life and cost-effectiveness.
    Conclusion: The results of this study will show the clinical applicability of STP activity in selecting recurrent ovarian cancer patients for effective therapies.
    Sprache Englisch
    Erscheinungsdatum 2023-12-01
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 2835763-2
    ISSN 2405-8440
    ISSN 2405-8440
    DOI 10.1016/j.heliyon.2023.e23170
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC).

    Rovers, Koen P / Lurvink, Robin J / Wassenaar, Emma Ce / Kootstra, Thomas Jm / Scholten, Harm J / Tajzai, Rudaba / Deenen, Maarten J / Nederend, Joost / Lahaye, Max J / Huysentruyt, Clément Jr / van 't Erve, Iris / Fijneman, Remond Ja / Constantinides, Alexander / Kranenburg, Onno / Los, Maartje / Thijs, Anna Mj / Creemers, Geert-Jan M / Burger, Jacobus Wa / Wiezer, Marinus J /
    Boerma, Djamila / Nienhuijs, Simon W / de Hingh, Ignace Hjt

    BMJ open

    2019  Band 9, Heft 7, Seite(n) e030408

    Abstract: Introduction: Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) is offered as a palliative treatment option for patients with isolated unresectable colorectal peritoneal metastases (PM) in several ... ...

    Abstract Introduction: Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) is offered as a palliative treatment option for patients with isolated unresectable colorectal peritoneal metastases (PM) in several centres worldwide. However, little is known about its feasibility, safety, tolerability, efficacy, costs and pharmacokinetics in this setting. This study aims to explore these parameters in patients with isolated unresectable colorectal PM who receive repetitive ePIPAC-OX as a palliative monotherapy.
    Methods and analysis: This multicentre, open-label, single-arm, phase II study is performed in two Dutch tertiary referral hospitals for the surgical treatment of colorectal PM. Eligible patients are adults who have histologically or cytologically proven isolated unresectable PM of a colorectal or appendiceal carcinoma, a good performance status, adequate organ functions and no symptoms of gastrointestinal obstruction. Instead of standard palliative treatment, enrolled patients receive laparoscopy-controlled ePIPAC-OX (92 mg/m
    Ethics and dissemination: This study is approved by an ethics committee, the Dutch competent authority and the institutional review boards of both study centres. Results are intended for publication in peer-reviewed medical journals and for presentation to patients, healthcare professionals and other stakeholders.
    Trial registration number: NCT03246321, Pre-results; ISRCTN89947480, Pre-results; NTR6603, Pre-results; EudraCT: 2017-000927-29, Pre-results.
    Mesh-Begriff(e) Aerosols ; Antineoplastic Agents/administration & dosage ; Clinical Trials, Phase II as Topic ; Colorectal Neoplasms/pathology ; Humans ; Multicenter Studies as Topic ; Nebulizers and Vaporizers ; Netherlands ; Oxaliplatin/administration & dosage ; Palliative Care ; Peritoneal Neoplasms/drug therapy ; Peritoneal Neoplasms/secondary ; Pneumoperitoneum, Artificial ; Static Electricity
    Chemische Substanzen Aerosols ; Antineoplastic Agents ; Oxaliplatin (04ZR38536J)
    Sprache Englisch
    Erscheinungsdatum 2019-07-27
    Erscheinungsland England
    Dokumenttyp Clinical Trial Protocol ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2599832-8
    ISSN 2044-6055 ; 2044-6055
    ISSN (online) 2044-6055
    ISSN 2044-6055
    DOI 10.1136/bmjopen-2019-030408
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang